Memantine Hydrochloride Patent Expiration
Memantine Hydrochloride is Used for managing moderate to severe dementia of the Alzheimer's type. It was first introduced by Abbvie Inc
Memantine Hydrochloride Patents
Given below is the list of patents protecting Memantine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Namenda Xr |
US8039009 (Pediatric) | Modified release formulations of memantine oral dosage forms | Sep 24, 2029 | Abbvie |
| Namenda Xr | US8039009 | Modified release formulations of memantine oral dosage forms | Mar 24, 2029 | Abbvie |
| Namenda Xr |
US8168209 (Pediatric) | Method and composition for administering an NMDA receptor antagonist to a subject | May 22, 2026 | Abbvie |
| Namenda Xr |
US8173708 (Pediatric) | Method and composition for administering an NMDA receptor antagonist to a subject | May 22, 2026 | Abbvie |
| Namenda Xr |
US8283379 (Pediatric) | Methods and compositions for the treatment of CNS-related conditions | May 22, 2026 | Abbvie |
| Namenda Xr |
US8329752 (Pediatric) | Composition for administering an NMDA receptor antagonist to a subject | May 22, 2026 | Abbvie |
| Namenda Xr |
US8362085 (Pediatric) | Method for administering an NMDA receptor antagonist to a subject | May 22, 2026 | Abbvie |
| Namenda Xr |
US8598233 (Pediatric) | Method for administering an NMDA receptor antagonist to a subject | May 22, 2026 | Abbvie |
| Namenda Xr | US8168209 | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov 22, 2025
(Expired) | Abbvie |
| Namenda Xr | US8173708 | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov 22, 2025
(Expired) | Abbvie |
| Namenda Xr | US8283379 | Methods and compositions for the treatment of CNS-related conditions |
Nov 22, 2025
(Expired) | Abbvie |
| Namenda Xr | US8329752 | Composition for administering an NMDA receptor antagonist to a subject |
Nov 22, 2025
(Expired) | Abbvie |
| Namenda Xr | US8362085 | Method for administering an NMDA receptor antagonist to a subject |
Nov 22, 2025
(Expired) | Abbvie |
| Namenda Xr | US8598233 | Method for administering an NMDA receptor antagonist to a subject |
Nov 22, 2025
(Expired) | Abbvie |
| Namenda |
US5061703 (Pediatric) | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct 11, 2015
(Expired) | Abbvie |
| Namenda |
US5061703 (Pediatric) | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct 11, 2015
(Expired) | Allergan |
| Namenda Xr |
US5061703 (Pediatric) | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct 11, 2015
(Expired) | Abbvie |
| Namenda | US5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr 11, 2015
(Expired) | Abbvie |
| Namenda | US5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr 11, 2015
(Expired) | Allergan |
| Namenda Xr | US5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr 11, 2015
(Expired) | Abbvie |
Memantine Hydrochloride's Family Patents
